Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.nj.com/sports-news/2020/02/ac-milan-vs-torino-live-stream-21720-watch-zlatan-ibrahimovic-in-serie-a-onl
Are you over 18 and want to see adult content?
A complete backup of aajtak.intoday.in/story/shilpa-shetty-become-mother-surrogacy-child-daughter-name-shamisha-shetty-kundra-me
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://meadowscenter.org
Are you over 18 and want to see adult content?
A complete backup of https://gitmemory.com
Are you over 18 and want to see adult content?
A complete backup of https://onlinepokiesoz.com
Are you over 18 and want to see adult content?
A complete backup of https://hayward-pool.com
Are you over 18 and want to see adult content?
A complete backup of https://myweboasis.com
Are you over 18 and want to see adult content?
A complete backup of https://kidfriendlydc.com
Are you over 18 and want to see adult content?
A complete backup of https://cozre.jp
Are you over 18 and want to see adult content?
A complete backup of https://uniqlo.com
Are you over 18 and want to see adult content?
A complete backup of https://uhamru.cz
Are you over 18 and want to see adult content?
A complete backup of https://psdlearning.com
Are you over 18 and want to see adult content?
Text
indications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » BUSINESS ADVISORS Matt Abbott, MBA. Independent Consultant Los Angeles, California. Matt Abbott is a member of MAX BioPharma’s Business Advisory Board. Matt has two decades of experience advising companies across a range of business issues, including growth strategies, digital marketing, M&A, organization, pricing, cost reduction, complexity reduction and changemanagement.
MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS MAX BioPharma Announces Update to its Oncology Program and Lead DrugCandidates
MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » CROWDFUND HAIR LOSS REVERSAL EXPERIMENT Available drug treatments for hair loss are modestly effective at best and often plagued by unpleasant side effects. In male pattern baldness, hormonal and other factors lead to a shortened growth (anagen) phase of the hair follicle, resulting in deactivated hair stem cells and diminished hair growth. OXYSTEROLS REGULATE DIFFERENTIATION OF MESENCHYMAL STEM Oxysterols Regulate Differentiation of Mesenchymal Stem Cells: Pro-Bone and Anti-Fat Hoa Ton Kha, 1Benjamin Basseri, Daniel Shouhed, Jennifer Richardson, Sotirios Tetradis,2 Theodore J Hahn,1,3 and Farhad Parhami1 ABSTRACT: Pluripotent mesenchymal stem cells can undergo lineage-specific differentiation in adult organ- NOVEL OSTEOGENIC OXYSTEROLS INDUCE SPINAL FUSION IN VIVO Article Novel Oxysterols Have Pro-Osteogenic and Anti-Adipogenic Effects In Vitro and Induce Spinal Fusion In Vivo Jared S. Johnson1#, Vicente Meliton2#, Woo Kyun Kim2, Kwang-Bok Lee1, Jeffrey C. Wang1, KhanhLinh Nguyen3, Dongwon Yoo3, Michael E. Jung3, Elisa Atti4, Sotirios Tetradis4, Renata C. Pereira5, Clara Magyar6, Taya Nargizyan2, Theodore J. Hahn7, NOVEL SMALL MOLECULE OXYSTEROLS FOR REGULATION OF HEDGEHOG Novel Small Molecule Oxysterols for Regulation of Hedgehog Signaling, Bone Formation & Tumorigenesis www.maxbiopharma.com Farhad Parhami,Ph.D., M.B.A.
MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » SCIENTIFIC ADVISORS Michael E. Jung is a Distinguished Professor in the Department of Chemistry and Biochemistry at the University of California at Los Angeles (UCLA). He received his BA from Rice University (1969) and his Ph.D. from Columbia University (1973), both in Chemistry. After a one-year NATO Postdoctoral fellowship at the Eidgenossische Technische MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » SCIENTIFIC ADVISORS Michael E. Jung is a Distinguished Professor in the Department of Chemistry and Biochemistry at the University of California at Los Angeles (UCLA). He received his BA from Rice University (1969) and his Ph.D. from Columbia University (1973), both in Chemistry. After a one-year NATO Postdoctoral fellowship at the Eidgenossische Technische MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » MAX BIOPHARMA’S PLATFORM TECHNOLOGY Our platform technology consists of the examination of the regulatory effects of proprietary small molecule oxysterols that modulate cellular signaling pathways, including the Hedgehog and the Liver X Receptor pathways, on lineage-specific differentiation of pluripotent mesenchymal cells (i.e. mesenchymal stem cells) into various celltypes.
MAX BIOPHARMA ::: » HISTORY BEHIND THE NAME MAX BIOPHARMA In 1963 MAX BioPharma was created as one of the first pharmaceutical companies in Iran by the late Dr. Benjamin Parhami, father of Dr.Farhad Parhami.
MAX BIOPHARMA ::: » NEWS AND EVENTS Posted on September 16th, 2016. MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and fundable scores in2015.
MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » MAX BIOPHARMA REPORTS ON NOVEL MAX BioPharma scientists publish new paper titled “Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties”. MAX BIOPHARMA ::: » TERMS OF USE The MAX BioPharma website is designed for providing general information about the company’s research and development strategy, history, and product development. OXYSTEROLS REGULATE DIFFERENTIATION OF MESENCHYMAL STEM Oxysterols Regulate Differentiation of Mesenchymal Stem Cells: Pro-Bone and Anti-Fat Hoa Ton Kha, 1Benjamin Basseri, Daniel Shouhed, Jennifer Richardson, Sotirios Tetradis,2 Theodore J Hahn,1,3 and Farhad Parhami1 ABSTRACT: Pluripotent mesenchymal stem cells can undergo lineage-specific differentiation in adult organ- NOVEL OSTEOGENIC OXYSTEROLS INDUCE SPINAL FUSION IN VIVO Article Novel Oxysterols Have Pro-Osteogenic and Anti-Adipogenic Effects In Vitro and Induce Spinal Fusion In Vivo Jared S. Johnson1#, Vicente Meliton2#, Woo Kyun Kim2, Kwang-Bok Lee1, Jeffrey C. Wang1, KhanhLinh Nguyen3, Dongwon Yoo3, Michael E. Jung3, Elisa Atti4, Sotirios Tetradis4, Renata C. Pereira5, Clara Magyar6, Taya Nargizyan2, Theodore J. Hahn7, MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » BUSINESS ADVISORS Matt Abbott, MBA. Independent Consultant Los Angeles, California. Matt Abbott is a member of MAX BioPharma’s Business Advisory Board. Matt has two decades of experience advising companies across a range of business issues, including growth strategies, digital marketing, M&A, organization, pricing, cost reduction, complexity reduction and changemanagement.
MAX BIOPHARMA ::: » NEWS AND EVENTS Posted on September 16th, 2016. MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and fundable scores in2015.
MAX BIOPHARMA ::: » HISTORY BEHIND THE NAME MAX BIOPHARMA In 1963 MAX BioPharma was created as one of the first pharmaceutical companies in Iran by the late Dr. Benjamin Parhami, father of Dr.Farhad Parhami.
MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS MAX BioPharma Announces Update to its Oncology Program and Lead DrugCandidates
MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » CROWDFUND HAIR LOSS REVERSAL EXPERIMENT Available drug treatments for hair loss are modestly effective at best and often plagued by unpleasant side effects. In male pattern baldness, hormonal and other factors lead to a shortened growth (anagen) phase of the hair follicle, resulting in deactivated hair stem cells and diminished hair growth. MAX BIOPHARMA ::: » MAX BIOPHARMA RECEIVES SBIR PHASE 2 MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and NOVEL SMALL MOLECULE OXYSTEROLS FOR REGULATION OF HEDGEHOG Novel Small Molecule Oxysterols for Regulation of Hedgehog Signaling, Bone Formation & Tumorigenesis www.maxbiopharma.com Farhad Parhami,Ph.D., M.B.A.
MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitorsMAX BIOPHARMA
At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » SCIENTIFIC ADVISORS Michael E. Jung is a Distinguished Professor in the Department of Chemistry and Biochemistry at the University of California at Los Angeles (UCLA). He received his BA from Rice University (1969) and his Ph.D. from Columbia University (1973), both in Chemistry. After a one-year NATO Postdoctoral fellowship at the Eidgenossische Technische MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » HISTORY BEHIND THE NAME MAX BIOPHARMA In 1963 MAX BioPharma was created as one of the first pharmaceutical companies in Iran by the late Dr. Benjamin Parhami, father of Dr.Farhad Parhami.
MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » NEWS AND EVENTS Posted on September 16th, 2016. MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and fundable scores in2015.
MAX BIOPHARMA ::: » MAX BIOPHARMA REPORTS ON NOVEL MAX BioPharma scientists publish new paper titled “Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties”. MAX BIOPHARMA ::: » MAX BIOPHARMA SELECTED TO PRESENT AT MAX BioPharma selected to present at the LA BioMed Innovation Showcase to be held on September 13th, 2018 in Manhattan Beach, California. ←Acceptance into
NOVEL SMALL MOLECULE OXYSTEROLS FOR REGULATION OF HEDGEHOG Novel Small Molecule Oxysterols for Regulation of Hedgehog Signaling, Bone Formation & Tumorigenesis www.maxbiopharma.com Farhad Parhami,Ph.D., M.B.A.
MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS89 BIOPHARMA At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMAABOUT MAX BIOPHARMASCIENCE AND TECHNOLOGYNEWS AND EVENTSINVESTOR RELATIONS89 BIOPHARMA At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. MAX BIOPHARMA ::: » ABOUT MAX BIOPHARMA MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerousindications.
MAX BIOPHARMA ::: » NEWS AND EVENTS MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. MAX BIOPHARMA ::: » CONTACT US Contact Us. Thank you for your interest in learning more about MAX BioPharma. For more information about MAX BioPharma’s scientific and business endeavors, please contact us and we will be in touch shortly. Your Name (required) Your Email (required) Subject. Your Message. MAX BIOPHARMA ::: » PIPELINE Lung Cancer. Treatment of lung cancer remains an unmet medical challenge. Lung cancer is the leading cause of cancer death in the US. The American Cancer Society has estimated that in 2019 in the US, 228,150 people (116,440 men and 111,710 women) will be diagnosed with lung cancer, and that 142,670 people will die of lung cancer. MAX BIOPHARMA ::: » INVESTORS MAX BioPharma is currently seeking investors for a series A financing for the company. We seek investor partners with a successful track record of early stage investing in biotechnology startups who would also provide management and business development resources. MAX BIOPHARMA ::: » MANAGEMENT Frank Stappenbeck, Ph.D. (Director of Chemistry) Frank Stappenbeck is the Director of Chemistry at MAX BioPharma. Since joining the company in 2011, he has spent nearly two decades working with drug discovery teams in the pharmaceutical industry, efforts that have produced several clinical drug candidates (Elan Pharmaceuticals, ICOS Corporation, SGX-Pharmaceuticals and Fate Therapeutics). MAX BIOPHARMA ::: » BUSINESS ADVISORSSEE MORE ON MAXBIOPHARMA.COM MAX BIOPHARMA ::: » OXYSTEROL THERAPEUTICS® Oxysterol Therapeutics®. At MAX BioPharma, we are developing medicinal applications of oxysterol derivatives, mostly in orthopedic medicine, cancer, fibrosis and viral infections following an approach that we have coined Oxysterol Therapeutics®. Oxysterols are oxidized derivatives of cholesterol that, depending on the context, can be MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » OVERVIEW MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company is the leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES DISCOVERIES MAX BioPharma Announces Discoveries Regarding Drug Candidates forTargeting COVID-19
MAX BIOPHARMA ::: » SCIENTIFIC ADVISORS Michael E. Jung is a Distinguished Professor in the Department of Chemistry and Biochemistry at the University of California at Los Angeles (UCLA). He received his BA from Rice University (1969) and his Ph.D. from Columbia University (1973), both in Chemistry. After a one-year NATO Postdoctoral fellowship at the Eidgenossische Technische MAX BIOPHARMA ::: » MAX BIOPHARMA ANNOUNCES UPDATE TO ITS Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors MAX BIOPHARMA ::: » HISTORY BEHIND THE NAME MAX BIOPHARMA In 1963 MAX BioPharma was created as one of the first pharmaceutical companies in Iran by the late Dr. Benjamin Parhami, father of Dr.Farhad Parhami.
MAX BIOPHARMA ::: » MAX BIOPHARMA PUBLISHES FOLLOW UP MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program. MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Non-Small Cell LungCancer
MAX BIOPHARMA ::: » NEWS AND EVENTS Posted on September 16th, 2016. MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and fundable scores in2015.
MAX BIOPHARMA ::: » MAX BIOPHARMA REPORTS ON NOVEL MAX BioPharma scientists publish new paper titled “Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties”. MAX BIOPHARMA ::: » MAX BIOPHARMA SELECTED TO PRESENT AT MAX BioPharma selected to present at the LA BioMed Innovation Showcase to be held on September 13th, 2018 in Manhattan Beach, California. ←Acceptance into
NOVEL SMALL MOLECULE OXYSTEROLS FOR REGULATION OF HEDGEHOG Novel Small Molecule Oxysterols for Regulation of Hedgehog Signaling, Bone Formation & Tumorigenesis www.maxbiopharma.com Farhad Parhami,Ph.D., M.B.A.
* Home
* About MAX BioPharma * About MAX BioPharma* Overview
* Management
* Scientific Advisors* Business Advisors
* Introductory Video * Science and Technology * Science and Technology* Pipeline
* Oxysterol Therapeutics®* News and Events
* Investor Relations* Contact Company
HOME
BETTER HEALTH.
BRIGHTER FUTURE.
OUR VISION
At MAX BioPharma we aim to capitalize on key discoveries made several years ago while analyzing a previously understudied group of lipid molecules and their role in human health and disease. Leveraging combined expertise in the fields of cellular biology, lipid biochemistry and drug discovery, we work to build a new generation of therapeutic agents that can address unmet medical needs with some of the most fatal and debilitating human disorders, such as osteoporosis and pancreatic cancer. NEWS AND RECENT RELEASES * MAX BioPharma Announces Update to its Liver Fibrosis Program * MAX BioPharma Announces Update to its Oncology Program and LeadDrug Candidates
* MAX BioPharma Publishes Follow Up Manuscript on its OncologyProgram
* MAX BioPharma reports on novel oxysterol drug candidate for cancer * MAX BioPharma receives a Phase IIB award from the NationalInstitute of Aging
* MAX BioPharma selected to present at the LA BioMed InnovationShowcase
* Acceptance into NIH’s Commercialization Accelerator Program(CAP)
* Crowdfund Hair Loss Reversal Experiment * MAX BioPharma Awarded $1.7 Million to Fight Osteoporosis * MAX BioPharma participates in World Cancer Day Contact Us | Privacy Policy | Terms of Use Copyright © MAX BioPharma 2020Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0